Bio Pharma Dive
JUNE 14, 2024
The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange.
Pharmaceutical Technology
JUNE 14, 2024
If exercised, the option would allow Takeda to license the TKI olverembatinib outside China, Hong Kong, Macau, Taiwan and Russia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 14, 2024
The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.
Pharmaceutical Technology
JUNE 14, 2024
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).
Bio Pharma Dive
JUNE 14, 2024
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
Pharmaceutical Technology
JUNE 14, 2024
England’s NHS has reported an 18% increase in the number of people with non-diabetic hyperglycaemia, also known as pre-diabetes.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JUNE 14, 2024
Precision immunology company Santa Ana Bio has announced a substantial funding injection of $168m through Series A and B financing rounds.
Fierce Pharma
JUNE 14, 2024
Six months after Vertex earned a historic FDA approval for sickle cell d | Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent efficacy and durability of the treatment, which is the first ever to be developed using CRISPR gene editing technology.
Pharmaceutical Technology
JUNE 14, 2024
India-based Suven Pharmaceuticals has announced a definitive agreement to acquire a strategic controlling stake in Sapala Organics.
pharmaphorum
JUNE 14, 2024
Stay up-to-date with the latest news in clinical trials with highlights from NMD Pharma, Minoryx Therapeutics, Moonlake Immunotherapeutics, and Ipsen. Discover the groundbreaking developments from 10th to 14th June.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JUNE 14, 2024
After a successful trial, the UK NHS has become the first to permanently adopt a subscription payment model for new antibiotics.
Pharma Times
JUNE 14, 2024
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Fierce Pharma
JUNE 14, 2024
Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologi | In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride.
Pharma Times
JUNE 14, 2024
The installation will double the capacity of cancer genomic testing using robotic automation
Fierce Pharma
JUNE 14, 2024
In the wake of the Supreme Court’s decision to preserve mail-order access to the abortion pill mifepristone, leaders from across the industry are weighing in with their support. | In the wake of the Supreme Court’s decision to preserve mail-order access to the abortion pill mifepristone, leaders from across the industry are weighing in with their support.
Drug Discovery World
JUNE 14, 2024
Discovery Park has opened CoLab, a new shared lab facility in the UK. In partnership with Canterbury Christ Church University, CoLab has been designed for early-stage life science businesses, providing flexible bench space in a coworking environment. Dr Cornelia Wilson, Senior Lecturer and Academic Laboratory Director at Canterbury Christ Church University, said: “Finding lab space is too often a blocker for promising life science spin outs and start-ups, and CoLab exists to solve this.
Fierce Pharma
JUNE 14, 2024
A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body. | A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body, and it's facing two competitors.
Drug Discovery World
JUNE 14, 2024
Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023. Pioneering Medicines, Flagship’s in-house drug discovery and development unit, is responsible for leading the partnership with Pfizer, including driving the exp
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JUNE 14, 2024
Radiopharma firm Telix abandons Nasdaq listing plans Phil.
WCG Clinical
JUNE 14, 2024
Breaking Barriers: Reasons to Expand Site Cancer Clinical Trial Portfolios Download Breaking Barriers: Reasons to Expand Site Cancer Clinical Trial Portfolios Clinical trial research collaborations between physicians, hospital systems, and pharmaceutical companies are essential in advancing medical knowledge and improving patient care, particularly in cancer treatment.
pharmaphorum
JUNE 14, 2024
DeepWell gamifies breathing therapy for mental health Phil.
Pharmaceutical Commerce
JUNE 14, 2024
The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
XTalks
JUNE 14, 2024
Ontario, Canada’s largest province by population, is stepping up its commitment to the life sciences sector with an investment of $40 million. The investment was announced by Vic Fedeli, Minister of Economic Development, Job Creation and Trade, at the Biotechnology Innovation Organization (BIO) International Convention, the world’s largest life sciences conference, in San Diego last week.
Pharmaceutical Commerce
JUNE 14, 2024
In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.
Drug Discovery World
JUNE 14, 2024
News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation to CAR-T therapies. The top stories: Gene therapy restores hearing in both ears Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therap
pharmaphorum
JUNE 14, 2024
Join the 3rd Operationalise: Early Access Programmes Summit Europe to gain insights and strategies for successful early access programs. Learn from industry experts and network with peers at this premier event.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Advarra
JUNE 14, 2024
A regulatory binder is essential for managing clinical trial documents, ensuring regulatory compliance, and facilitating audits. It organizes critical documents; provides easy access for trial monitors, auditors, and regulatory authorities; and serves as a reference for the research team. Though not legally binding, maintaining a regulatory binder is highly recommended for all intervention trials.
pharmaphorum
JUNE 14, 2024
Discover the latest trends and developments in Real World Evidence (RWE) at the 12th IMPACCT Real World Evidence Summit. Explore how RWE is transforming drug development and healthcare outcomes.
XTalks
JUNE 14, 2024
Healthcare private equity faces increasing scrutiny with the introduction of the Corporate Crimes Against Health Care Act of 2024. This new legislation, spearheaded by US senators Elizabeth Warren and Ed Markey from Massachusetts, aims to address the significant issues arising from corporate and private equity abuses in the healthcare sector. Key Provisions of the Bill The proposed bill introduces stringent measures to curb financial misconduct in healthcare.
pharmaphorum
JUNE 14, 2024
Explore the latest trends and innovations in wearable injectors and connected devices at the Wearable Injectors and Connected Devices USA conference. Join industry leaders and experts for valuable insights and networking opportunities.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
164 
Let's personalize your content